<DOC>
	<DOCNO>NCT00642824</DOCNO>
	<brief_summary>This single arm genetic substudy MO19390 test hypothesis positive relationship mRNA BRCAI level response different chemotherapy combination plus Avastin . A subset patient participate MO19390 , receive Avastin 15mg/kg iv day 1 subsequently every 3 week , undergo BRCAI mRNA expression determination . Depending BRCAI mRNA level ( low , medium high ) receive different chemotherapy regimen combination Avastin : ) gemcitabine/cisplatin , b ) vinorelbine + cisplatin/docetaxel + cisplatin c ) vinorelbine docetaxel . Avastin treatment continue completion chemotherapy cycle disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Genetic Substudy Associated With Avastin ( Bevacizumab ) Study MO19390 Patients With Advanced Recurrent Non-Squamous Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>participate , meet inclusion/exclusion criterion , MO19390 . meeting inclusion/exclusion criterion MO19390 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>